An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
Latest Information Update: 09 May 2025
At a glance
- Drugs Cedazuridine/decitabine (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Astex Pharmaceuticals; Taiho Oncology
Most Recent Events
- 07 Mar 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2027.
- 07 Mar 2025 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2027.
- 02 Dec 2024 Planned End Date changed from 31 Jan 2025 to 31 Dec 2025.